BioCryst Pharmaceuticals Inc Total Liabilities
BioCryst Pharmaceuticals Inc total liabilities. Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has total liabilities worth $1.02 Billion USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BioCryst Pharmaceuticals Inc (BCRX) liquidity interval to measure how many days the company can operate on defensive assets alone.
Total Liabilities of BioCryst Pharmaceuticals Inc (1994–2025)
Total liabilities of BioCryst Pharmaceuticals Inc from 1994 to 2025. This chart illustrates how BioCryst Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check BCRX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
BioCryst Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Empresas Cablevisión S.A.B. de C.V
MX:CABLECPO
|
Mexico | MX$9.44 Billion |
|
V2X Inc
NYSE:VVX
|
USA | $2.10 Billion |
|
Mednax Inc
NYSE:MD
|
USA | $1.25 Billion |
|
Endeavour Silver Corp.
TO:EDR
|
Canada | CA$558.89 Million |
|
Foran Energy Group Co Ltd
SHE:002911
|
China | CN¥10.61 Billion |
|
Electric Connector Technology Co Ltd
SHE:300679
|
China | CN¥2.30 Billion |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
USA | $1.06 Billion |
|
Immunome Inc
NASDAQ:IMNM
|
USA | $40.30 Million |
Liability Composition Analysis (1994–2025)
This chart breaks down BioCryst Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see BioCryst Pharmaceuticals Inc asset portfolio.
Liquidity & Leverage Metrics
BioCryst Pharmaceuticals Inc Total Liabilities Ratios Explained
BioCryst Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.84 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioCryst Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual total liabilities of BioCryst Pharmaceuticals Inc from 1994 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $633.31 Million | -34.46% |
| 2024-12-31 | $966.35 Million | -0.63% |
| 2023-12-31 | $972.49 Million | +15.14% |
| 2022-12-31 | $844.60 Million | +21.50% |
| 2021-12-31 | $695.14 Million | +96.38% |
| 2020-12-31 | $353.98 Million | +158.32% |
| 2019-12-31 | $137.03 Million | +40.39% |
| 2018-12-31 | $97.61 Million | +3.30% |
| 2017-12-31 | $94.49 Million | +7.05% |
| 2016-12-31 | $88.27 Million | +14.89% |
| 2015-12-31 | $76.83 Million | +25.46% |
| 2014-12-31 | $61.24 Million | +22.50% |
| 2013-12-31 | $49.99 Million | -13.65% |
| 2012-12-31 | $57.89 Million | -14.11% |
| 2011-12-31 | $67.40 Million | +53.38% |
| 2010-12-31 | $43.94 Million | -21.42% |
| 2009-12-31 | $55.92 Million | +46.15% |
| 2008-12-31 | $38.27 Million | -50.82% |
| 2007-12-31 | $77.81 Million | +64.40% |
| 2006-12-31 | $47.33 Million | +15.98% |
| 2005-12-31 | $40.81 Million | +1201.96% |
| 2004-12-31 | $3.13 Million | +90.08% |
| 2003-12-31 | $1.65 Million | +40.63% |
| 2002-12-31 | $1.17 Million | -48.63% |
| 2001-12-31 | $2.28 Million | -75.58% |
| 2000-12-31 | $9.35 Million | +367.27% |
| 1999-12-31 | $2.00 Million | +42.86% |
| 1998-12-31 | $1.40 Million | +16.67% |
| 1997-12-31 | $1.20 Million | -29.41% |
| 1996-12-31 | $1.70 Million | -5.56% |
| 1995-12-31 | $1.80 Million | +12.50% |
| 1994-12-31 | $1.60 Million | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more